Ergomed (AIM:ERGO) - Aktienkurs, Nachrichten und Analyse

ERGO Aktienübersicht

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally.

Über das Unternehmen

ERGO grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	0/6
Künftiges Wachstum	3/6
Vergangene Leistung	3/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Prognostiziertes Gewinnwachstum 14.17% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 12.3%

Risikoanalyse

Volatiler Aktienkurs in den letzten 3 Monaten

Die Aktionäre wurden im vergangenen Jahr verwässert

Ergomed plc Wettbewerber

hVIVO

AIM:HVO

UK£185.7m

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Genus

LSE:GNS

UK£1.1b

Bioventix

AIM:BVXP

UK£227.1m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Ergomed
Historische Aktienkurse
Aktueller Aktienkurs	UK£13.46
52-Wochen-Hoch	UK£13.80
52-Wochen-Tief	UK£8.95
Beta	0.79
11 Monat Veränderung	0.90%
3 Monate Veränderung	21.26%
1 Jahr Veränderung	3.54%
33 Jahre Veränderung	67.41%
5 Jahre Veränderung	812.54%
Veränderung seit IPO	728.31%

Aktuelle Nachrichten und Updates

Recent updates

If You Had Bought Ergomed (LON:ERGO) Stock Five Years Ago, You Could Pocket A 643% Gain Today

Feb 22

Has Ergomed plc's (LON:ERGO) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Jan 18

Ergomed plc's (LON:ERGO) Intrinsic Value Is Potentially 20% Below Its Share Price

Dec 13

We Think Ergomed's (LON:ERGO) Statutory Profit Might Understate Its Earnings Potential

Nov 23

Aktionärsrenditen

	ERGO	GB Life Sciences	GB Markt
7D	0.1%	-6.8%	1.1%
1Y	3.5%	-43.6%	8.1%

Rendite im Vergleich zur Industrie: ERGO übertraf die Branche UK Life Sciences, die im vergangenen Jahr eine Rendite von -42.9 erzielte.

Rendite vs. Markt: ERGO übertraf den Markt UK, der im vergangenen Jahr eine Rendite von 6.9 erzielte.

Preisvolatilität

Is ERGO's price volatile compared to industry and market?
ERGO volatility
ERGO Average Weekly Movement	8.1%
Life Sciences Industry Average Movement	7.1%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.1%
10% least volatile stocks in GB Market	2.7%

Stabiler Aktienkurs: ERGODer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: ERGODie wöchentliche Volatilität (8%) war im letzten Jahr stabil, liegt aber immer noch höher als bei 75 % der UK Aktien.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1997	1,400	n/a	www.ergomedplc.com

Ergomed plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Ergomed im Vergleich zum Marktanteil des Unternehmens?
ERGO grundlegende Statistiken
Marktanteil	UK£701.05m
Gewinn(TTM)	UK£15.00m
Umsatz(TTM)	UK£152.09m

46.7x

Kurs-Gewinn-Verhältnis

4.6x

Kurs-Umsatz-Verhältnis

Ist ERGO zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ERGO Gewinn- und Verlustrechnung (TTM)
Einnahmen	UK£152.09m
Kosten der Einnahmen	UK£68.82m
Bruttogewinn	UK£83.27m
Sonstige Ausgaben	UK£68.27m
Umsatz	UK£15.00m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.29
Bruttomarge	54.75%
Nettogewinnspanne	9.86%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich ERGO auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ERGO Aktienübersicht

Belohnungen

Risikoanalyse

Ergomed plc Wettbewerber

AIM:HVO

UK£185.7m

AIM:C4XD

UK£30.3m

LSE:GNS

UK£1.1b

AIM:BVXP

UK£227.1m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Now 20% undervalued after recent price drop

Is It Time To Consider Buying Ergomed plc (LON:ERGO)?

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ergomed plc, Annual General Meeting, Jun 22, 2023

At UK£9.74, Is Ergomed plc (LON:ERGO) Worth Looking At Closely?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Ergomed plc (LON:ERGO) Shares Could Be 21% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Should You Be Adding Ergomed (LON:ERGO) To Your Watchlist Today?

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings: EPS misses analyst expectations

Ergomed plc, Annual General Meeting, Jun 10, 2022

Consensus EPS estimates increase by 11%

Consensus forecasts updated

Less than half of directors are independent

Now 21% undervalued

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Full year 2021 earnings: EPS misses analyst expectations

Does Ergomed (LON:ERGO) Deserve A Spot On Your Watchlist?

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Why Ergomed plc (LON:ERGO) Could Be Worth Watching

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

I Ran A Stock Scan For Earnings Growth And Ergomed (LON:ERGO) Passed With Ease

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Calculating The Intrinsic Value Of Ergomed plc (LON:ERGO)

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Ergomed (LON:ERGO) Before It's Too Late

Getting In Cheap On Ergomed plc (LON:ERGO) Might Be Difficult

Ergomed plc (LON:ERGO) Shares Could Be 31% Above Their Intrinsic Value Estimate

Price target increased to UK£13.65

Non-Executive Director has left the company

Investor sentiment improved over the past week

Do Ergomed's (LON:ERGO) Earnings Warrant Your Attention?

Full year 2020 earnings released

Erträge & Einnahmen